$0.38
-0.01 (-1.80%)
Open$0.38
Previous Close$0.38
Day High$0.38
Day Low$0.38
52W High$2.00
52W Low$0.28
Volume—
Avg Volume337.4K
Market Cap8.37M
P/E Ratio—
EPS$-1.27
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+10,718.8% upside
Current
$0.38
$0.38
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 731.6K | 1.39M | 2.02M |
| Net Income | -50,659,034 | -86,662,479 | 234.8K |
| Profit Margin | -6,925.2% | -6,578.9% | 11.6% |
| EBITDA | -56,050,956 | -101,213,473 | 368.8K |
| Free Cash Flow | — | — | 168.2K |
| Rev Growth | -47.4% | -47.4% | +14.4% |
| Debt/Equity | 0.33 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |